Health economics and outcomes research (HEOR) has become a principal way of assessing effectiveness and appropriate cost. It is used along with clinical information (i.e. safety, efficacy, quality etc.) to guide key decision makers regarding patient access to specific drugs and services.
With substantial demand for comparative effectiveness evidence, biopharmaceutical organizations anticipate further growth in HEOR data utilization. Consequently, many companies are developing health outcomes capabilities to better inform decision-making about pricing, reimbursement, inclusion of drugs on formularies and treatment guidelines. In fact, many organizations have a dedicated HEOR group that oversees all the responsibilities around health outcomes.
As the responsibilities of the HEOR function grow, it is important to optimize the group’s operations for maximum impact. Key aspects of the HEOR function that can be optimized include role differentiation, data utilization, Health Outcomes Liaison (HOL) program structure and resources, and customer engagement tactics.
However, health outcomes groups often face challenges in leveraging HOLs, optimizing group structure and successfully utilizing health outcomes information to provide data on product value that is appropriate for the different perspectives of the stakeholders in the health care system.
Best Practices, LLC’s Health Outcomes studies deliver best practices and benchmarks around key elements such as: Health Outcomes data utilization, HOL program structure and resources, HOL role differentiation and customer engagement tactics.
Developed through benchmarking best-in-class organizations, these studies enable biopharmaceutical and medical device organizations to fully leverage the HOL function in an increasingly challenging business environment. Distilled from insights of executives from leading companies, our studies highlight current and upcoming trends, as well as performance benchmarks, best practices, winning strategies and lessons learned.